Zhaoyan Pharmaceutical (06127) has abnormal fluctuations in A-share trading, and there is no significant information that should have been disclosed but not disclosed

According to Zhitong Finance App News, Zhaoyan New Pharmaceutical (06127) announced that the daily closing price increase deviation value of the company's A-share shares accumulated over 3 consecutive trading days on July 14, July 15, and July 16, 2026. According to the relevant provisions of the “Shanghai Stock Exchange Trading Rules”, it is a situation where stock trading fluctuates abnormally.

After self-inspection, the company's current production and operation activities are normal, there have been no major changes in the internal or external business environment, and there is no significant information affecting the abnormal fluctuations in the company's stock trading price that should have been disclosed but not disclosed.

The company disclosed its 2026 semi-annual results forecast on July 15, 2026. It is expected to achieve net profit attributable to shareholders of listed companies of about RMB 600 million to RMB 900 million from January to June 2026, an increase of about 884.9% to 1,377.4%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses is expected to be approximately RMB 561 million to 842 million yuan from January to June 2026, an increase of about 2,334.2% to 3,551.3% year-on-year. Among them: Net profit from changes in fair value of biological assets is approximately RMB 703 million to 777 million yuan; net profit from laboratory services and other businesses is approximately RMB 142 million to RMB 64.9736 million.